StockData
Twist Bioscience Corp logo

Twist Bioscience Corp (TWST) company profile

TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-K on Nov 16, 2026Score 13/30207% above fair value
$105.04−6.56 (-5.88%)

Close on Nov 16, 2026Market cap $6.59BP/E –Yield –

About Twist Bioscience

Biological Products, (No Diagnostic Substances), SIC 2836

Twist Bioscience Corporation is a synthetic biology company that manufactures synthetic DNA using a proprietary silicon chip platform. Its primary offerings comprise synthetic biology tools—such as clonal genes, gene fragments, oligo pools, and IgG proteins—and next-generation sequencing products, including target enrichment panels and library preparation kits. In addition, the company provides biopharma solutions for antibody discovery, optimization, and characterization. It sells products and services to biopharmaceutical companies, diagnostic laboratories, agricultural enterprises, chemical manufacturers, and academic research institutions.

The company serves more than 3,800 customers worldwide across the healthcare, industrial chemicals, academic, and agricultural sectors. Twist Bioscience maintains manufacturing and operations facilities in South San Francisco, California, and Wilsonville, Oregon, supported by commercial personnel and consultants in Europe and Asia. Its principal manufacturing and operational base is located in South San Francisco, California.

Summary of the business section of Twist Bioscience's latest annual report, written by StockData.

Company profile

Company

Legal name
Twist Bioscience Corp
Founded
2013
Headquarters
South San Francisco, CA
Address
681 Gateway Blvd. 94080
Phone
(800) 719-0671
Employees
979, Sep 30, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
September 30
Auditor
Ernst & Young LLP, San Mateo, California

Stock & identifiers

Ticker
TWST
Exchange
Nasdaq
IPO date
Nov 1, 2018
Shares outstanding
63M, Jul 29, 2026
Public float
$2.32B, Mar 31, 2025
Filer category
Large accelerated filer
SEC CIK
1581280
CUSIP
90184D100
ISIN
US90184D1000
FIGI
BBG006KDCHJ4
Share class FIGI
BBG006KDCHK2
LEI
549300T23BL59LCOH584
EIN
46-2058888

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Emily M. LeproustChief Executive Officer, Director656,044
Patrick John FinnPresident and COO233,913
Paula GreenSVP of Human Resources126,054
Adam LaponisChief Financial Officer124,860
Dennis ChoSee Remarks85,665
Robert F. WernerChief Accounting Officer51,208
Katryn BlakeDirector17,208
Robert ChessDirector63,612
Melissa A. StarovasnikDirector22,222
Jan JohannessenDirector29,754
Keith CrandellDirector103,618
Robert P. RagusaDirector28,983
Nelson ChanDirector33,251

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$13.78M$928.13K$4.80M$37$119
FY2024$7.62M$24.98M$2.68M$59$116
FY2023$8.00M$3.22M$3.09M$27$95
FY2022$5.92M-$15.04M$2.48M$46$90
FY2021$1.28M$18.05M$728.15K$141$120

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Emily M. Leproust, Ph.D.
Chief Executive Officer and Chair of the Board
$720.00K$12.00M$932.92K$130.52K$13.78M+81%
Adam Laponis
Chief Financial Officer
$490.00K$3.37M$349.20K$11.49K$4.22M-16%
Patrick Finn, Ph.D.
President and Chief Operating Officer
$563.00K$6.75M$583.59K$127.40K$8.02M+108%
Paula Green
Senior Vice President of Human Resources
$400.00K$2.57M$259.14K$119.18K$3.35M+67%
Dennis Cho
Chief Legal Officer and Corporate Secretary
$449.00K$2.87M$290.89K$9.13K$3.62M+101%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 1, 2018
Offer price
$14.00
Securities offered
5,000,000
Gross proceeds
$70.00M
Exchange
Nasdaq
First trading day
Oct 31, 2018
First-day close
$14.000.0%
Lock-up ends (est.)
Apr 29, 2019

“The initial public offering price is $14.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of September 30, 2025, we had 979 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?